230 related articles for article (PubMed ID: 29703174)
1. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.
Mähringer-Kunz A; Weinmann A; Schmidtmann I; Koch S; Schotten S; Pinto Dos Santos D; Pitton MB; Dueber C; Galle PR; Kloeckner R
BMC Cancer; 2018 Apr; 18(1):489. PubMed ID: 29703174
[TBL] [Abstract][Full Text] [Related]
2. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
4. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
Kloeckner R; Pitton MB; Dueber C; Schmidtmann I; Galle PR; Koch S; Wörns MA; Weinmann A
J Vasc Interv Radiol; 2017 Jan; 28(1):94-102. PubMed ID: 27562621
[TBL] [Abstract][Full Text] [Related]
5. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH
Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
[TBL] [Abstract][Full Text] [Related]
6. Outcome of inoperable hepatocellular carcinoma patients receiving transarterial chemoembolisation: a real-life retrospective analysis in a Hong Kong regional hospital.
Yip WM; Hung HG; Lok KH; Li KF; Li KK; Szeto ML
Hong Kong Med J; 2009 Oct; 15(5):339-45. PubMed ID: 19801690
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation.
Mishra G; Dev A; Paul E; Cheung W; Koukounaras J; Jhamb A; Marginson B; Lim BG; Simkin P; Borsaru A; Burnes J; Goodwin M; Ramachandra V; Spanger M; Lubel J; Gow P; Sood S; Thompson A; Ryan M; Nicoll A; Bell S; Majeed A; Kemp W; Roberts SK;
BMC Cancer; 2020 May; 20(1):483. PubMed ID: 32471447
[TBL] [Abstract][Full Text] [Related]
8. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
[TBL] [Abstract][Full Text] [Related]
9. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
10. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
11. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
12. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Pai M; Reccia I; Patel M; Giakoustidis A; Karamanakos G; Rushd A; Jamshaid S; Oldani A; Grossi G; Pirisi M; Tait P; Sharma R
BMC Cancer; 2018 Feb; 18(1):211. PubMed ID: 29463228
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.
Xue T; Le F; Chen R; Xie X; Zhang L; Ge N; Chen Y; Wang Y; Zhang B; Ye S; Ren Z
Med Oncol; 2015 Mar; 32(3):64. PubMed ID: 25682389
[TBL] [Abstract][Full Text] [Related]
14. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
[TBL] [Abstract][Full Text] [Related]
15. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
16. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
[TBL] [Abstract][Full Text] [Related]
18. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
19. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma.
Vogeler M; Mohr I; Pfeiffenberger J; Sprengel SD; Klauss M; Teufel A; Chang DH; Springfeld C; Longerich T; Merle U; Mehrabi A; Weiss KH; Mieth M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1033-1050. PubMed ID: 32107625
[TBL] [Abstract][Full Text] [Related]
20. Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis.
Qiao W; Sheng S; Xiong Y; Han M; Jin R; Hu C
Front Immunol; 2024; 15():1369988. PubMed ID: 38799452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
